New Zealand markets closed

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.4600-0.0800 (-3.15%)
As of 10:27AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.5400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4400 - 2.5700
52-week range1.5000 - 4.7500
Avg. volume44,586
Market cap93.377M
Beta (5Y monthly)1.71
PE ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • Insider Monkey

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript March 20, 2024 DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Full Year 2023 Conference Call. An […]

  • Simply Wall St.

    DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability

    With the business potentially at an important milestone, we thought we'd take a closer look at DiaMedica Therapeutics...

  • Business Wire

    DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

    MINNEAPOLIS, March 19, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023. Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.